Evercore ISI raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $185 and keeps an In Line rating on the shares as the firm updates estimates and makes several tactical calls in the Healthcare Technology & Distribution group ahead of Q3 earnings season.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $190 from $185 at Barclays
- Guardant Health, Quest Diagnostics announce blood-based screening test pact
- Quest Diagnostics partners with Epic for streamlined laboratory testing
- Haystack Oncology, Rutgers Cancer Institute collaborate to study Haystack MRD
- Quest Diagnostics: Strong Growth Prospects and Operational Efficiency Justify Buy Rating